INTRODUCTION
A ge-related macular degeneration (AMD) is usually complicated by progressive visual impairment. It seriously affects patient quality of life, especially in aged individuals. It is an irreversible disease that causes blindness. It is the third most common cause worldwide and the most common cause in Western countries for irreversible blindness in elderly. AMD morbidity in Asia has also increased. Although AMD is not the leading cause of vision loss in China, AMD morbidity is rising as the Chinese population ages. An epidemiological study found the rate of AMD morbidity to be as high as 15.5% in developed cities in China [1] . Choroidal neovascularization (CNV)
is an important pathological characteristic of wet age-related macular degeneration (wAMD). Lack of timely intervention may result in a very poor prognosis; visual acuity may decrease by 3 lines within 1y and by 4 lines within 2y [2] [3] . Therefore, the appropriate diagnosis and treatment of this disease requires more attention. The pathogenesis of CNV has not yet been fully revealed, but vascular endothelial growth factors (VEGFs) have been found to play an important role in its development [4] . VEGF-A can promote the division and proliferation of vascular endothelial cells and neovascularization; additionally, it maintains the survival of new vessels. VEGF-A is an inflammatory cell chemotactic factor [5] [6] . It also increases vascular permeability [7] . High VEGF-A expression has been detected in surgically isolated samples of newly formed vessel membranes associated with wAMD [8] [9] . VEGF suppression is an ideal treatment for wAMD. 92 Ranibizumab is a recombinant humanized monoclonal antibody. Its receptor binding site is VEGF-A, which is known to promote vascular generation and leakage and to cause wAMD. The binding of ranibizumab prevents and hinders the interaction of vascular receptors (VEGFR1 and VEGFR2) on the surfaces of vascular endothelial cells, inhibits vascular endothelial hyperplasia, and reduces both vascular leakage into the macular region and the development of CNV. In 2006, the Food and Drug Administration (FDA) approved the use of intravitreal ranibizumab injections for the treatment of wAMD. The State Food and Drug Authority of China approved its clinical use in December 2011. A randomized controlled trial with a 6-month follow-up is the only available study on the use of ranibizumab in Chinese patients [3] , and there is a great need for obtaining more clinical data on the use of this novel drug in treating wAMD. Hence, the present study aimed to evaluate the clinical efficacy and safety of ranibizumab for the treatment of wAMD in Chinese patients and to determine the mean number of injections administered over one year of follow-up.
SUBJECTS AND METHODS
The study was in compliance with the policies described in the DRCR.net Policies document (www.drcr.net), with the ethical principles of the Declaration of Helsinki and with the standards of Good Clinical Practice. Subjects It was a single centre, retrospective observational case series study. Male and female Chinese patients were included if they met the following inclusion criteria: were ≥50 years of age, had CNV secondary to AMD (including classic, minimally classic, and occult CNV), had not accepted other treatments (including laser therapy, photodynamic therapy, and intravitreal injections of triamcinolone and bevacizumab), had no history of recent onset short-term active arrhythmia or apoplexy, were willing and able to sign the informed consent form; and were followed for the entire 12-month period. Initially, a total of 220 patients who were treated for wAMD at the Department of Ophthalmology, People's Hospital, Peking University of China between February 2012 and June 2013 were considered for enrolment into the study. The total number of injections was 956. Of the patients, 50 were excluded because they were observed for less than one year, and 49 were excluded because they had polypoid choroidal vasculopathy (PCV). Hence, data from only 121 patients (70 eyes from 70 males and 51 eyes from 51 females; 121 eyes total) were included in the study. Intervention and Observation Procedures All patients had vision testing, intraocular tension measurement, slit-lamp microscopy, indirect ophthalmoscopy, colour fundus photography, fundus fluorescein angiography (FFA), and indocyanine green choroidal angiography (ICGA). Central retinal thickness was measured by optical coherence tomography (OCT).
Three types of CNV were observed among the patients: classic, minimally classic, and occult. Before the operation, the patients routinely received levofloxacin eye drops for 3d. The injection was performed using a strictly aseptic technique in an operating room. Following surface anaesthesia with 0.4% oxybuprocaine eye drops, the needle was inserted into the eye to be operated on, 3.5 mm behind the corneoscleral junction below the nose or the temple, and ranibizumab 0.5 mg (Lucentis; produced in Switzerland; supported by Beijing Novartis Pharma Co., Ltd.) was injected into the vitreous cavities. Injections were performed once per month for 3mo and as needed afterwards (PRN). Vision testing and OCT were conducted each month. FFA and ICGA were performed when necessary. Follow-up was performed on day 1, day 3, and each month until 12mo after the operation. Levofloxacin eye drops were given for 3d after the operation. The subsidence of macular edema and CNV leakage was considered to be indicative of recovery from the events. FFA and ICGA were performed during the treatment if necessary. If a patient developed PCV, he/she was removed from the study and was recommended for PDT and transpupillary thermotherapy. Main Outcome Measures Significant visual acuity improvement, significant visual acuity decrease, and stable visual acuity were defined as follows: visual acuity increase ≥15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, visual acuity decrease <15 ETDRS letters, and visual acuity change within 15 letters, respectively. Responses were defined as subsidence and reduction in FFA leakage. The use of the PrONTO criteria was recommended for continued and repeated treatments. The following findings were compared to previous follow-up results: intraretinal fluid/cyst persistence on OCT, visual acuity decrease ≥5 ETDRS letters and macular edema on OCT, central retinal thickness increase ≥100 µm in any of the scanning lines in the 6 directions on OCT, new macular bleeding, new type of CNV foci, any organic change in OCT indicating the recurrence of macular edema (including cystoid retinal edema), subretinal edema, and increased retinal pigment epithelium. Central foveal thickness (CFT) was measured using the Humphrey 2000 OCT system, scanning line length: 4000 μm (Carl Zeiss Opthalmic System, Humphrey Division, Dubin, Califormia, USA). CFT and visual acuity were recorded at baseline and during each month of the 12-month follow-up period. Visual acuity and OCT morphology were established as the two primary indicators for assessing treatment efficacy. Adverse Events Patients with one or more adverse events related to the drugs and injections were recorded for further adverse events analysis. The adverse events included the following: endophthalmitis, severe uveitis, retinal detachment, vitreous haemorrhage, related thromboembolism, suspected , and significantly decreased in only 2.5% of the patients (3 eyes). The improvement in patients' visual acuity was particularly pronounced at the first two follow-up visits after treatment. The visual acuity variation curves were similar to those reported in previous literature (Figure 2 ). This study also found that CFT decreased with prolonged treatment duration ( Figure 3 ). In addition, the relationship between baseline CFT and the decrease in CFT after treatment was analysed using Spearman's correlation. The correlation coefficient was 0.748 (P<0.001). This corresponded to the clinical phenomenon that the patients with more serious central foveal edema improved to a greater extent after treatment (Figure 4) . baseline CFT was greater than that of the total variance of the increase in visual acuity explained by baseline CFT and visual acuity (adjusted R 2 : 0.659 vs 0.083; Table 2 ). Complications No generalized complications occurred in the study population. None of out patients had the adverse events during the follow-up period as listed: endophthalmitis, severe uveitis, retinal detachment, vitreous haemorrhage, related thromboembolism, suspected sensitivity to Lucentis, permanent foveal injury, and poor visual acuity without edema. Small-area subconjunctival haemorrhage occurred in 20 of the patients; however, no other ophthalmic complications were reported (Figures 5, 6 ).
DISCUSSION
Morbidity related to wAMD has increased from year to year as the life expectancy of the Chinese population has risen. The disease prognosis is very poor if wAMD is not treated in a timely manner. VEGFs are recognized as the most important angiogenic stimulating factors and play important roles in the generation and development of new vessels [4] .
Ranibizumab, which was designed as a Fab fragment, has a high binding affinity and low molecular weight, which are optimal for bioactivity; additionally, it binds with high affinity to the VEGF-A receptor binding sites to inhibit cascade reactions that would occur following the binding of VEGF-A to its receptors. It inhibits wAMD through the following mechanisms: inhibiting endothelial cell proliferation to hinder the development of CNV and inhibiting vascular permeation and inflammatory reactions to reduce leakage and edema [10] . Monthly injections of ranibizumab may prevent visual acuity loss in patients with wAMD. This has been reported in the MARINA and ANCHOR studies [11] [12] . Since its official release date in China, ranibizumab has become the only legal anti-VEGF product in the country. However, considering its administration method and high price, it is imperative to investigate how many injections are needed to cure wAMD in Chinese patients. Recent studies indicate that injections given monthly and PRN afterwards are equivalent in therapeutic effect [13] [14] . A 3+PRN treatment modality was recommended by PrONTO [15] . The results showed that the efficacy of 3+PRN is similar to that of monthly injection, despite the fact that it requires a significantly lower number of injections; consecutive injections over the first 3mo rapidly improved visual acuity to a plateau, and monthly maintenance afterwards preserved but did not further improve visual acuity. The Chinese Ophthalmological Society 2013 guidelines for AMD recommend VEGF therapy as the first-line treatment for wAMD; the therapy involves 3 consecutive injections at the beginning and treatment PRN afterwards [16] . The criteria for retreatment in this study were based on noninvasive OCT for follow-up monitoring and judgment, and the PrONTO [15] study was referenced. However, considering the high PCV morbidity in China, FFA and ICGA were performed, as appropriate, and patients with established PCV were excluded. The data of patients who received ranibizumab treatment and were followed for more than one year were summarized. The results showed that, after one year of treatment, visual acuity stabilized or improved in 97.1% of the patients (118 eyes); the visual acuity at one year improved compared to the baseline, and the difference was statistically significant. The CFT also significantly decreased compared to the baseline value, and the difference was also statistically significant. The mean number of injections over one year was 5.1, which is very similar to the findings of studies conducted in European countries and America (Table 3) . Over the past decade, a number of multicentre clinical studies on the treatment of AMD in foreign countries with high-level after seven injections. Before the operation, the patient's visual acuity was 35 letters; macular haemorrhage was present; CNV leakage was present; and OCT showed that the CFT was 543 μm. After seven injections, visual acuity increased to 75 letters; haemorrhage was absorbed;
FFA showed subsidence of CNV leakage and only scar staining; and OCT showed that the CFT decreased to 234 μm. The effects were stable until month 12. A, B, C, and D: Preoperative; E, F, G and H: Postoperative.
evidence have been carried out. However, many uncertain problems concerning AMD treatment need to be explored; in China, this exploration is still in its initial period. Due to the short marketing history of ranibizumab in China, data on longer treatment durations and larger patient populations are not available. Therefore, it is imperative to continue observation in future research to improve the levels of AMD diagnosis and treatment, which would benefit more patients. Based on the findings of this study and other studies in various countries, it is clear that wAMD is manageable and that a specific treatment duration can produce positive results is not endless. Nevertheless, the process is long and requires the confidence of patients and oculists so that the quality of life of the elderly population in China may be improved. The retrospective nature of this study and the lack of a control group are the most critical study limitations. Based on the currently available data, it can be concluded that intravitreal injection of ranibizumab is safe and effective for treating wAMD in Chinese people; additionally, the mean number of injections over the first year was 5.1. Prospective studies of longer duration and with larger sample sizes are needed to further verify the efficacy and safety of ranibizumab. [14] Multicentre 285 6.9 6.9
PrONTO (Philip J. Rosenfeld et al, 2009 ) [15] America 40 5.6 5.6
Muniraju et al, 2013 [17] Britain 174 4.8 3.0 SUSTAIN (Holz et al, 2011) [18] Multicentre 513 5.6 5.6
Arias et al, 2011 [19] Spain 90 4.4 4.4
Bandukwala et al, 2010 [20] Canada 94 5.1 5.1
Hjelmqvist et al, 2011 [21] Sweden 370 4.7 4.7
Kumar et al, 2011 [22] Britain 81 5.6 5.6
Williams and Blyth, 2011 [23] Britain 615 5.6 5.6
Present study China 91 5.1 7.4
